Altiratinib - Deciphera Pharmaceuticals

Drug Profile

Altiratinib - Deciphera Pharmaceuticals

Alternative Names: DCC-22701; DCC-2701; DP-5164

Latest Information Update: 16 Feb 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Deciphera Pharmaceuticals
  • Class Amides; Antineoplastics; Cyclopropanes; Dicarboxylic acids; Pyridines; Small molecules
  • Mechanism of Action Mitogen-activated protein kinase inhibitors; Proto oncogene protein c met inhibitors; TIE 2 receptor antagonists; TrkA receptor antagonists; TrkB receptor antagonists; TrkC receptor antagonists; Vascular endothelial growth factor receptor-2 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Glioblastoma
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase I Solid tumours
  • Preclinical Glioblastoma

Most Recent Events

  • 30 Jan 2018 Phase-I development is ongoing in Solid-tumours in USA (PO, Tablet)
  • 30 Jan 2018 Deciphera Pharmaceuticals LLC terminates a phase I trial in Solid tumours (Late-stage disease, Metastatic disease, Second-line therapy or greater) in USA (PO) (NCT02228811)
  • 04 Nov 2017 No recent reports of development identified for phase-I development in Solid-tumours in USA (PO, Tablet)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top